Alicante, 01 July 2026

COMMUNICATION – MARKET NOTICE - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "Facephi" or "the Company") hereby notifies the following:

> During the Ordinary General Shareholders' Meeting of FACEPHI BIOMETRÍA, S.A. (hereinafter, "FACEPHI" or the "Company"), held on 30 June 2026 on second call, with the attendance of a total of 20 shareholders, either in person or duly represented, representing 42.89% of the Company's share capital, all of the resolutions submitted for voting were approved in accordance with the notice convening the General Shareholders' Meeting previously published.

The following items are adopted:

FIRST. – Examination and approval of the annual financial statements (comprising the balance sheet, the profit and loss account, the statement of changes in equity, the statement of cash flows and the notes to the financial statements), together with the management report corresponding to the financial year ended 31 December 2025.

The aforementioned annual financial statements were published on the websites of BME Growth and the Company on 4 May 2026. Likewise, these annual financial statements were audited by KPMG AUDITORES, S.L., which issued its independent auditor's report on 4 May 2026 expressing a qualified opinion.

It is proposed to approve the aforementioned annual financial statements for the 2025 financial year, as prepared by the Company's Board of Directors on 31 March 2026.

Approved unanimously.

SECOND. – Examination and approval of the consolidated annual financial statements (comprising the consolidated balance sheet, the consolidated profit and loss account, the consolidated statement of changes in equity, the consolidated statement of cash flows and the notes to the consolidated financial statements), together with the consolidated management report corresponding to the financial year ended 31 December 2025.

The aforementioned consolidated annual financial statements were published on the websites of BME Growth and the Company on 4 May 2026. Likewise, these consolidated annual financial statements were audited by KPMG AUDITORES, S.L., which issued its independent auditor's report on 4 May 2026 expressing a qualified opinion.

It is proposed to approve the aforementioned consolidated annual financial statements for the 2025 financial year, as prepared by the Company's Board of Directors on 31 March 2026.

Approved unanimously.

THIRD. – Examination and approval, where appropriate, of the proposal for the allocation of the Company's results for the 2025 financial year.

As indicated in Note 11.d to the notes to the financial statements for the 2025 financial year, the Company has obtained a positive result for the year of EUR 413,065. The proposal of the Board of Directors submitted for voting consists of allocating the entire profit for the financial year to offset the item "Negative results from previous financial years" for offsetting in future financial years.

Approved unanimously.

FOURTH. – Examination and approval, where appropriate, of the management carried out by the Company's Board of Directors corresponding to the 2025 financial year.

To approve the management of the Board of Directors during the financial year ended 31 December 2025, in view of the Management Report, which has previously been submitted for approval. Said report has been made available to the shareholders and, in accordance with the terms of the notice of meeting, those who so requested have been able to obtain it immediately and free of charge and to examine it at the Company's offices.

Approved by majority of 93,9%.

FIFTH. – Approval, where appropriate, of the remuneration to be received by the executive officers of the Company, as well as by the members of the Board of Directors during the 2026 financial year.

The remuneration of the Governing Body and the Board of Directors of the Company for the 2026 financial year is approved, in accordance with the meeting of the Appointments and Remuneration Committee of FACEPHI BIOMETRÍA, S.A. held on 26 May 2026.

It is proposed to maintain the overall remuneration of the Board at the current amount of EUR 440,000. The distribution of such amount among the members of the Board shall depend on criteria of length of service in office, dedication, performance in their respective positions, responsiveness and availability, qualifications, and the responsibility attached to each position.

Approved by majority of 93,9%.

SIXTH. – Proposal and approval, where appropriate, of the re-election of the members of the Board of Directors Mr. Javier Mira Miró, Mr. Juan Alfonso Ortiz Company and Mr. Pablo Reig Boronat.

It is proposed that the General Meeting approve the re-election of the members of the Board of Directors Mr. Javier Mira Miró, Mr. Juan Alfonso Ortiz Company and Mr. Pablo Reig Boronat for the statutory term of six years.

Approved by majority of 93,9%.

SEVENTH. – Strengthening of the Company's corporate governance structure by increasing the number of members of the Board of Directors. Authorization for the Board to be composed of seven members instead of the current five members.

It is proposed that the General Meeting approve the increase in the number of members of the Board of Directors for the purpose of strengthening the corporate governance structure, increasing the number of Board members from five to seven.

Approved unanimously.

EIGHTH. – Authorization to the Board of Directors so that any of its members may, within the framework of the Tax Lease transaction agreed with Leyton, execute such public and/or private documents as they may deem appropriate or necessary for the execution, formalization, execution by public deed, amendment, novation, restatement, ratification, implementation, rectification, correction, supplementation, clarification and/or cancellation of the documents relating to said transaction, including, in particular but without limitation, the granting of an irrevocable power of attorney to LEYTON IMPULSE, S.L.U. in relation to the Framework Agreement and the Put Option Agreement, so that it may execute, among other ancillary documents, the public deed of sale and purchase of the participation interests in the AIE in the name and on behalf of Facephi

Biometría, S.A., even where this involves cases of self-dealing, dual representation, multiple representation, conflict of interest or delegation.

It is proposed to authorize the Board of Directors so that any of its members may, within the framework of the Tax Lease transaction agreed with Leyton, execute such public and/or private documents as they may deem appropriate or necessary for the execution, formalization, execution by public deed, amendment, novation, restatement, ratification, implementation, rectification, correction, supplementation, clarification and/or cancellation of the documents relating to said transaction, including, in particular but without limitation, the granting of an irrevocable power of attorney to LEYTON IMPULSE, S.L.U. in relation to the Framework Agreement and the Put Option Agreement, so that it may execute, among other ancillary documents, the public deed of sale and purchase of the participation interests in the AIE in the name and on behalf of Facephi Biometría, S.A., even where this involves cases of self-dealing, dual representation, multiple representation, conflict of interest or delegation.

Approved by majority of 99,9%.

NINTH. – Delegation of powers

It is proposed to delegate to the Chairman and the Secretary of the Board all acts necessary to execute the resolutions adopted by means of a public deed.

Approved unanimously.

TENTH. – Questions and answers

As no additional questions were raised, this item is declared concluded and the meeting proceeds to the next item.

ELEVENTH. – Where appropriate, drafting, reading and approval of the minutes of the General Meeting

The minutes are then drawn up and signed.

We remain at your disposal for any clarifications you may require.

Yours faithfully,

Javier Mira Miró

Chairman of the Board of Directors